B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5

B of A Securities analyst Craig Bijou has maintained an 'Underperform' rating on RxSight (NASDAQ: RXST) and reduced the price target from $6.5 to $5.5.